Research graph
References from Molecular sampling limits of ctDNA detection in clinical plasma samples. Local targets link to admitted publications; unresolved targets remain external evidence.
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO precision medicine working group
10.1016/j.annonc.2022.05.520 · 2022 · External reference
Implementing the ESMO recommendations for the use of circulating tumor DNA (ctDNA) assays in routine clinical application/diagnostics
10.1515/labmed-2024-0029 · 2024 · External reference
The emerging role of cell-free DNA as a molecular marker for cancer management
10.1016/j.bdq.2019.100087 · 2019 · External reference
Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer
10.1016/j.esmoop.2022.100399 · 2022 · External reference
A field guide for cancer diagnostics using cell-free DNA: from principles to practice and clinical applications
10.1002/gcc.22517 · 2018 · External reference
Current and future perspectives of liquid biopsies in genomics-driven oncology
10.1038/s41576-018-0071-5 · 2019 · External reference
ctDNA applications and integration in colorectal cancer: an NCI Colon and rectal-anal task forces white paper
10.1038/s41571-020-0392-0 · 2020 · External reference
Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics
10.1038/s41551-021-00837-3 · 2022 · External reference
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
10.1038/s41587-021-00857-z · 2021 · External reference
A clinician's handbook for using ctDNA throughout the patient journey
10.1186/s12943-022-01551-7 · 2022 · External reference
Improvement of the sensitivity of circulating tumor DNA-based liquid biopsy: current approaches and future perspectives
10.37349/etat.2025.1002333 · 2025 · External reference
DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism
10.1038/s41591-024-03195-0 · 2024 · External reference
Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay
10.1038/s41467-025-56658-4 · 2025 · External reference
Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment
10.1038/s41591-024-03040-4 · 2024 · External reference
International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors
10.1016/j.jlb.2025.100301 · 2025 · External reference
Unresolved reference
2023 · External reference
The changing face of circulating tumor DNA (ctDNA) profiling: factors that shape the landscape of methodologies, technologies, and commercialization
2023 · External reference
Unresolved reference
2026 · External reference
Data analysis
2016 · External reference
Unresolved reference
External reference
10.32614/cran.package.tidyr
10.32614/cran.package.tidyr · External reference
10.32614/cran.package.readr
10.32614/cran.package.readr · External reference
10.32614/cran.package.patchwork
10.32614/cran.package.patchwork · External reference
10.32614/cran.package.scales
10.32614/cran.package.scales · External reference
Minimum technical preanalytical, patient, and clinical context data elements for cerebrospinal fluid liquid biopsy: recommendations for public database submissions
2025 · External reference
